NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line ABRYSVO® vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 clinical trial (NCT05035212) RENOIR (RSV vaccine Efficacy study iN Older adults Immunized against RSV disease). Vaccine efficacy against RSV-associated lower respiratory tract disease (LRTD), defined by three or more sym ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced the presentation of 64 abstracts that includes highlights of the company’s next-generation pipeline advancements, alongside data from its diverse portfolio of marketed HIV treatment and prevention options at the Conference on Retroviruses and Opportunistic Infections (CROI 2024) being held in Denver, Colorado, from 3 – 6 March 2024. Kimberly Smith, M.D ...

New York, United States, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Increasing Prevalence of Cancer Cachexia to Drive the Global Cancer Cachexia Market According to the International Agency for Research on Cancer-Globocan 2020 report, there will be 19,292,789 new cancer cases and 9,958,133 cancer-related deaths globally in 2020. Globally, it was estimated that there were 50,550,287 occurrences of cancer over five years. The global incidence of new cancer cases is projected to reach 28,887,940 by 2040. Moreover, acco ...

With Pfizer (PFE -2.09%) stock hovering near a five-year low, one analyst has just started coverage of the pharmaceutical giant and is telling investors it's time to buy. In a report released last week, Guggenheim analyst Vamil Divan said he believes Pfizer is worth $36 per share. That would represent a gain of about 30% from Friday's closing price.Pfizer's cash generated from operations soared during the COVID-19 pandemic, and its share price soared along with it. But Pfizer stock has dropped by more than ...

JuSun Introduction I've written a lot about how overvalued dividend stocks have been during the past 4 years. Other than a brief period in March 2020, when a few good higher-yield stocks were trading at attractive valuations, the massive influx of Baby Boomers going into retirement combined with a decade of low bond yields pushed many investors into stocks who were seeking income from dividends. While most dividend stocks are still in a bubble, there is one that has been left for dead by investors: Pfiz ...

--VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU-- SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company")'s partner Pfizer Inc. (NYSE: PFE) announced that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-3619 PFIZER INC. (Exact name of registrant as specified in its charter) Delaware 13-5315170 (State or other jurisdiction of incorporation ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugmaker have returned -3% over the past month versus the Zacks S&P 500 composite's +3% change. The Zacks Large Cap Pharmaceuticals industry, to which Pfizer belongs, has gained 6.9% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports or rum ...

Pfizer (PFE) announced that the European Commission has granted marketing approval to its oral, once-daily pill called Velsipity (etrasimod) to treat moderately to severely active ulcerative colitis (UC).The approval for the oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator (2 mg dose) is for UC patients who are 16 years of age and older and who have had an inadequate response, lost response, or were intolerant to either conventional therapy or injectable therapies like biologics. ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has granted marketing authorization for VELSIPITY® (etrasimod) in the European Union to treat patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent. “For the 2.6 million people in Europe living with UC, the unpredictable physical, mental, and ...